Persistence and Adherence to PCSK9 Inhibitor Monoclonal Antibodies Versus Ezetimibe in Real-World Settings.

Paul MuntnerLama GhaziJenna JonesNafeesa DhalwaniBharat PoudelYing WenLigong ChenZhixin WangVera BittnerBethany KalichMichael E FarkouhMark WoodwardLisandro D ColantonioRobert S Rosenson

Published in: Advances in therapy (2024)

These data suggest approaches to increase persistence and adherence to PCSK9i mAb and ezetimibe should be implemented prior to or within 182 days following treatment initiation.

Keyphrases

type diabetes
combination therapy
metabolic syndrome
adipose tissue
artificial intelligence